Opendata, web and dolomites

OZONELASER

Cost and time-effective universal medical device for treatment of onychomycosis by combining several technologies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "OZONELASER" data sheet

The following table provides information about the project.

Coordinator
TERMOSALUD SL 

Organization address
address: CL ATAULFO FRIERA TARFE 8 PG CAMPO
city: GIJON
postcode: 33211
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.termosalud.com/Actualidad/Cost-and-time-effective-universal-medical-device-for-treatment-of-oncychomycosis/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-05-01   to  2016-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TERMOSALUD SL ES (GIJON) coordinator 50˙000.00

Map

 Project objective

TERMOSALUD, S.L., hereinafter TSALUD, is an Spanish SME whose core business is Well-being, Health and Medical–Esthetic industry. Currently, TSALUD goal is the development of specialized medical equipment oriented to dermatology within Medical–Esthetic business line: new Derma business line. OZONELASER project is oriented to create a new product within “Derma” field in order to provide dermatogological treatments (for nails, skins or hairs) and diagnosis for a fungal infection (onychomycosis or OM) based on cell technologies. While competitors use treatment solutions based on drugs or on (high or low) laser technologies, OZONELASER will be the unique commercial product based on a combination of two technologies which provides high efficiency, low prizes, universality on the type of patient to be treated, short treatment periods, painless and natural tissue regeneration by fostering own body cells growth. Likewise, patients cannot develop resistance to OZONELASER while they do to current existing treatments based on antifungals. Thus, OZONELASER will provide a solution for treatment and diagnosis of a fungal infection on finfernails and toenails which affects 10% of worldwide population, specially on elderly which in 2060 it will represent around the 50% of worldwide population and only in USA it represents a 16 billion € market. In addition, TSALUD has a long-term strategy for such Derma business line. This will be further improved through new developments. TSALUD bases this New Market Strategy on SME Instrument to reduce OZONELASER time to market (accelerate startegic partner selection, collection of user needs, IPR protection, etc.) as it is known how medical devices require long-term developments due to clinical trials

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OZONELASER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OZONELASER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More